Company Overview - Acadia Healthcare Company, Inc. (ACHC) is currently experiencing significant attention in the options market, particularly with the December 20, 2024 $90 Call option showing high implied volatility, indicating expectations of a substantial price movement [1] Analyst Sentiment - Acadia Healthcare holds a Zacks Rank of 5 (Strong Sell) within the Medical – Hospital industry, which is positioned in the top 32% of the Zacks Industry Rank [3] - Over the past 60 days, there have been no increases in earnings estimates for the current quarter, while five analysts have reduced their estimates, leading to a decrease in the Zacks Consensus Estimate from $0.85 to $0.74 per share [3] Options Market Dynamics - The high implied volatility surrounding Acadia Healthcare suggests that options traders anticipate a significant price movement, which could indicate an upcoming event that may lead to either a rally or a sell-off [2][4] - Options traders often seek to sell premium on options with high implied volatility, aiming to benefit from the decay of the option's value if the underlying stock does not move as much as expected by expiration [4]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Acadia Healthcare Company, Inc. securities of a lead plaintiff deadline in a securities class action lawsuit, emphasizing the potential for compensation without out-of-pocket costs for eligible investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between February 28, 2020, and October 18, 2024, with a lead plaintiff deadline set for December 16, 2024 [1][3]. - Investors who purchased Acadia Healthcare securities during the specified period may be entitled to compensation through a contingency fee arrangement [2][3]. Group 2: Allegations Against Acadia Healthcare - The lawsuit alleges that Acadia Healthcare made materially false and misleading statements regarding its business practices, including holding vulnerable individuals against their will and subjecting patients to abuse [5]. - It is claimed that Acadia Healthcare deceived insurance providers into covering unnecessary stays in its facilities, leading to misleading statements about its operations and prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. and certain senior executives, alleging misrepresentation of financial results related to insurance fraud and improper patient detainment practices [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Dyar v. Acadia Healthcare Company, Inc., No. 3:24-cv-01300 [2]. - Investors have until December 16, 2024, to request to be appointed to lead the case [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. Group 2: Allegations Against Acadia - Acadia is one of the largest for-profit chains of psychiatric hospitals in the U.S. [3]. - The complaint alleges that Acadia misrepresented its financial results, claiming they were driven by insurance fraud and holding vulnerable individuals against their will [3]. - A New York Times investigation highlighted that Acadia lured patients and detained them without medical necessity, contributing to a decline in stock price [4]. Group 3: Stock Price Impact - Following the New York Times article on September 1, 2024, Acadia's stock fell by $3.72 per share, or 4.5%, closing at $78.21 on September 3, 2024 [4]. - On September 27, 2024, Acadia disclosed receiving requests for information from the U.S. Attorney's Office and a grand jury subpoena, leading to a 16% decline in stock price from $75.66 to $63.28 per share [5]. - An October 18, 2024, article reported an investigation by the Veterans Affairs Department into potential insurance fraud, causing a 12% drop in stock price from $59.32 to $52.03 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Acadia Healthcare Company, Inc. securities between February 28, 2020, and October 18, 2024, about the December 16, 2024, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Acadia Healthcare securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6] - The deadline to move the Court to serve as lead plaintiff is December 16, 2024, with the lead plaintiff acting on behalf of other class members [3] Group 2: Case Allegations - The lawsuit alleges that Acadia Healthcare made materially false and misleading statements regarding its business practices, including holding vulnerable individuals against their will and subjecting them to abuse [5] - It is claimed that Acadia deceived insurance providers into covering unnecessary stays in its facilities, leading to misleading statements about the company's operations and prospects [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions for investors [4] - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 [4]

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. and certain senior executives, alleging misrepresentation of financial results related to insurance fraud and improper patient detainment practices [1][3]. Legal Proceedings - Investors have until December 16, 2024, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Dyar v. Acadia Healthcare Company, Inc. [2]. Allegations - The lawsuit claims that Acadia misrepresented its financial performance, attributing it to fraudulent practices and holding patients against their will when not medically necessary [3]. Stock Price Impact - Following a New York Times article on September 1, 2024, which detailed Acadia's practices, the stock price fell by $3.72 (4.5%) to $78.21 on September 3, 2024 [4]. - On September 27, 2024, Acadia disclosed receiving requests for information from the U.S. Attorney's Office and a grand jury subpoena, leading to a 16% decline in stock price from $75.66 to $63.28 [5]. - An October 18, 2024, article reported an investigation by the Veterans Affairs Department into potential insurance fraud, causing a 12% drop in stock price from $59.32 to $52.03 [6]. Company Background - Acadia Healthcare is one of the largest for-profit chains of psychiatric hospitals in the United States [3].

Core Viewpoint - A securities class action lawsuit has been filed against Acadia Healthcare Company, Inc. for allegedly making false and misleading statements regarding its business practices and patient treatment during the Class Period from February 28, 2020, to October 18, 2024 [1]. Group 1: Allegations Against Acadia Healthcare - The lawsuit claims that Acadia Healthcare's business model involved holding vulnerable individuals against their will in facilities, even when not medically necessary [3]. - It is alleged that many patients in Acadia Healthcare facilities experienced abuse [3]. - The company is accused of deceiving insurance providers into covering unnecessary stays for patients in its facilities [3]. - As a result of these practices, the statements made by Acadia Healthcare regarding its business operations and prospects were deemed materially false and misleading [3]. Group 2: Legal Process and Participation - Investors in Acadia Healthcare have until December 16, 2024, to seek appointment as a lead plaintiff representative in the class action lawsuit [4]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [4]. - Investors can choose to participate actively or remain as absent class members without affecting their ability to share in any recovery [4]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for recovering billions for victims of corporate misconduct [6]. - The firm encourages affected investors to contact them for more information regarding the lawsuit [5].

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. and certain senior executives, alleging misrepresentation of financial results related to insurance fraud and improper patient detainment practices [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until December 16, 2024, to request to lead the case [2]. Group 2: Allegations Against Acadia - Acadia is one of the largest for-profit psychiatric hospital chains in the U.S., accused of holding patients against their will and misrepresenting financial results [3]. - A New York Times investigation revealed that Acadia's success was partly due to these disturbing practices, leading to a stock price drop of $3.72 per share (4.5%) on September 3, 2024 [4]. Group 3: Regulatory Scrutiny - On September 27, 2024, Acadia disclosed receiving requests for information from the U.S. Attorney's Office and a grand jury subpoena, resulting in a 16% decline in stock price from $75.66 to $63.28 per share [5]. - An October 18, 2024, article indicated that the Veterans Affairs Department is investigating Acadia for potential insurance fraud, causing a further 12% decline in stock price from $59.32 to $52.03 per share [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Acadia Healthcare between February 28, 2020 and September 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW Y ...

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a lawsuit against Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and certain of the Company’s senior executives. If you invested in Acadia Healthcare, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/acadia-healthcare-company-inc. Investors have until December 16, 2024 to ask the Court to be appointed to lead the case. The c ...

Core Viewpoint - A class action lawsuit has been filed against Acadia Healthcare Company, alleging that the company held patients against their will and engaged in misleading practices regarding its business model and billing [1][2]. Group 1: Allegations and Complaints - The lawsuit claims that Acadia Healthcare's business model involved holding vulnerable patients against their will, even when it was not medically necessary [2]. - It is alleged that many patients experienced abuse while in Acadia's facilities [2]. - The company is accused of deceiving insurance providers into covering costs for patients who did not require hospitalization [2]. Group 2: Stock Price Impact - Following a New York Times article detailing the allegations, Acadia's stock price dropped by $3.72 per share, or 4.5%, closing at $78.21 on September 3, 2024 [3]. - After Acadia disclosed receiving a grand jury subpoena related to its admissions and billing practices, the stock fell by $12.38 per share, or 6.36%, closing at $63.28 on September 27, 2024 [4]. Group 3: Class Action Participation - Investors who purchased Acadia Healthcare securities between February 28, 2020, and September 26, 2024, may be eligible to participate in the class action [1]. - Shareholders interested in serving as lead plaintiffs must submit their applications by December 16, 2024 [5].